Leticia G. León
YOU?
Author Swipe
View article: The interconnection between androgen receptor and DNA damage response pathways in prostate cancer
The interconnection between androgen receptor and DNA damage response pathways in prostate cancer Open
The androgen receptor (AR) plays a critical role in the development and progression of prostate cancer by regulating key cellular processes such as cell proliferation and apoptosis. Although traditional AR-targeted therapies have shown ini…
View article: Armored human CAR T <sub>reg</sub> cells with PD1 promoter-driven IL-10 have enhanced suppressive function
Armored human CAR T <sub>reg</sub> cells with PD1 promoter-driven IL-10 have enhanced suppressive function Open
Regulatory T cell (T reg cell) therapy has been transformed through the use of chimeric antigen receptors (CARs). We previously found that human T reg cells minimally produce IL-10 and have a limited capacity to control innate immunity com…
View article: Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells
Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells Open
Allogeneic T cell therapies are a highly desirable option to circumvent the cost and complexity of using autologous T cells to treat diseases. Allogeneic CD8+ T cells can be made from pluripotent stem cells (PSCs), but deriving CD4+ T cell…
View article: Supplementary Figure 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
Supplementary Figure 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Supplementary Figure 1. Comparison of losses between cases and controls.
View article: TABLE 3 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
TABLE 3 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Univariate conditional logistic regression analysis to determine the association of the presence of AA, molecular high-risk adenoma (CAEs, any DNA CNAs, losses, or gains) with the development of a me-CRC
View article: Supplementary Figure 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
Supplementary Figure 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Supplementary Figure 1. Comparison of losses between cases and controls.
View article: Supplementary Figure 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
Supplementary Figure 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Supplementary Figure 2 shows a Kaplan-Meier analysis evaluating the timing of development of me-CRC in advanced adenomas with or without molecular high-risk features.
View article: TABLE 5 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
TABLE 5 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Multivariate conditional logistic regression analysis to determine the association of age, the presence of AA, molecular high-risk adenoma (losses or gains) with the development of a me-CRC
View article: TABLE 3 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
TABLE 3 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Univariate conditional logistic regression analysis to determine the association of the presence of AA, molecular high-risk adenoma (CAEs, any DNA CNAs, losses, or gains) with the development of a me-CRC
View article: TABLE 4 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
TABLE 4 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Multivariate conditional logistic regression analysis to determine the joint association of age, the presence of AA, molecular high-risk adenoma (CAEs, any DNA CNAs) with the development of a me-CRC
View article: TABLE 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
TABLE 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Characteristics of matched cases and controls of the adenoma cohort
View article: TABLE 4 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
TABLE 4 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Multivariate conditional logistic regression analysis to determine the joint association of age, the presence of AA, molecular high-risk adenoma (CAEs, any DNA CNAs) with the development of a me-CRC
View article: FIGURE 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
FIGURE 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Flowchart of the selection and analysis of the study cases. A, Selection of samples with complete molecular and morphologic information available. B, Selection of samples used in the case–control comparison (incidence density…
View article: FIGURE 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
FIGURE 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Proportion of molecular high-risk adenomas among the AAs (A) and non-AAs (B). Molecular high-risk adenomas are defined by the presence of ≥2 CAEs.
View article: TABLE 5 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
TABLE 5 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Multivariate conditional logistic regression analysis to determine the association of age, the presence of AA, molecular high-risk adenoma (losses or gains) with the development of a me-CRC
View article: Supplementary Figure 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
Supplementary Figure 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Supplementary Figure 2 shows a Kaplan-Meier analysis evaluating the timing of development of me-CRC in advanced adenomas with or without molecular high-risk features.
View article: TABLE 7 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
TABLE 7 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Stratified time analysis showing the effect of molecular risk definitions (CAEs or losses) and the morphologic risk definition of adenoma on developing me-CRC
View article: Data from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
Data from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Current morphologic features defining advanced adenomas (size ≥10 mm, high-grade dysplasia or ≥25% villous component) cannot optimally distinguish individuals at high risk or low risk of metachronous colorectal cancer (me-CRC), which may r…
View article: TABLE 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
TABLE 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Characteristics of matched cases and controls of the adenoma cohort
View article: FIGURE 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
FIGURE 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Proportion of molecular high-risk adenomas among the AAs (A) and non-AAs (B). Molecular high-risk adenomas are defined by the presence of ≥2 CAEs.
View article: FIGURE 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
FIGURE 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Flowchart of the selection and analysis of the study cases. A, Selection of samples with complete molecular and morphologic information available. B, Selection of samples used in the case–control comparison (incidence density…
View article: TABLE 6 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
TABLE 6 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Comparisons of subgroups to explore the interaction between morphologic and molecular risk definitions in the association with me-CRC risk
View article: Data from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
Data from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Current morphologic features defining advanced adenomas (size ≥10 mm, high-grade dysplasia or ≥25% villous component) cannot optimally distinguish individuals at high risk or low risk of metachronous colorectal cancer (me-CRC), which may r…
View article: TABLE 6 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
TABLE 6 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Comparisons of subgroups to explore the interaction between morphologic and molecular risk definitions in the association with me-CRC risk
View article: TABLE 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
TABLE 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Distribution of the morphologic and molecular classifications of the adenomas included in the study
View article: TABLE 7 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
TABLE 7 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Stratified time analysis showing the effect of molecular risk definitions (CAEs or losses) and the morphologic risk definition of adenoma on developing me-CRC
View article: TABLE 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
TABLE 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Distribution of the morphologic and molecular classifications of the adenomas included in the study
View article: Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study
Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study Open
Current morphologic features defining advanced adenomas (size ≥10 mm, high-grade dysplasia or ≥25% villous component) cannot optimally distinguish individuals at high risk or low risk of metachronous colorectal cancer (me-CRC), which may r…
View article: Supplementary Figures 1-5 from MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity
Supplementary Figures 1-5 from MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity Open
Supplementary Figures 1-5 from MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity
View article: Supplementary Figures 1-5 from MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity
Supplementary Figures 1-5 from MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity Open
Supplementary Figures 1-5 from MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity